Clinical trials: Frontline
Breast Cancer
A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer
This multicenter, observational, prospective study will identify a powerful and easy predictive/prognostic marker to use with participants under bevacizumab.
- Trial name
- Argo (NCT02613208)
- Testing
- Bevacizumab, Paclitaxel
- Where
- 25 sites in Spain
- Volunteers
- 111 people
- Sponsor
- Hoffmann-La Roche
Leukemia
Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI
RATIONALE: Tyrosine kinase inhibitors may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Interferon alfa may interfere with the growth of cancer cells.
- Trial name
- NCT00363649
- Testing
- GM-K562 cell vaccine, Interferon alfa, Sargramostim
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia
This phase II trial studies how well azacitidine and venetoclax with or without pembrolizumab work in treating older patients with newly diagnosed acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Secondary Acute Myeloid Leukemia
- Trial name
- NCT04284787
- Testing
- Azacitidine, Biopsy Procedure, Biospecimen Collection
- Where
- 29 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy, such as fludarabine, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00096018
- Testing
- fludarabine phosphate, thalidomide
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Roswell Park Cancer Institute
Leukemia
Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)
The goal of this clinical research study is to compare how well 2 different dosing schedules of decitabine may help control AML.
- Trial name
- NCT01786343
- Testing
- Decitabine
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- M.D. Anderson Cancer Center
Extensive Stage Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma
Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer
This randomized phase II clinical trial studies whether the addition of nivolumab to cisplatin (or carboplatin) and etoposide will improve outcomes when treating patients with extensive stage small cell lung cancer.
- Trial name
- NCT03382561
- Testing
- Carboplatin, Cisplatin, Etoposide
- Where
- 779 sites in United States
- Volunteers
- 160 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma, Grade 3b
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
This is a Phase 2 study to evaluate the combination of denintuzumab mafodotin in combination with RCHOP or RCHP compared with RCHOP alone as front-line therapy in patients with diffuse large B-cell lymphoma or follicular lymphoma…
- Conditions
- Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma, Grade 3b, Transformed Lymphoma / DLBCL
- Trial name
- NCT02855359
- Testing
- denintuzumab mafodotin, rituximab, cyclophosphamide
- Where
- 35 sites in United States, Puerto Rico
- Volunteers
- 24 people
- Sponsor
- Seagen Inc.
Chronic Lymphocytic Leukemia
Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline
Primary Objective: To evaluate the efficacy (combined morphologic and flow remissions) of a combination of fludarabine, cyclophosphamide and multiple dose rituximab as frontline therapy for CLL.
- Trial name
- NCT00794820
- Testing
- Fludarabine Phosphate, Cyclophosphamide, Rituximab
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- M.D. Anderson Cancer Center
Anaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
This is a double-blind, randomized, multicenter, phase 3 clinical trial to compare the efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in patients with CD30-positive mature T-cell…
- Conditions
- Anaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma
- Trial name
- ECHELON-2 (NCT01777152)
- Testing
- brentuximab vedotin, doxorubicin, prednisone
- Where
- 144 sites in United States, Australia and 14 more
- Volunteers
- 452 people
- Sponsor
- Seagen Inc.
Alzheimer Disease, Dementia
Enhancing Sleep Quality for Nursing Home Residents With Dementia
This was a pilot study (R61) to prepare for a full clinical trial (R33) aiming to improve clinical outcomes for an important, growing, and vulnerable population-nursing home (NH) residents with Alzheimer's disease or related…
- Conditions
- Alzheimer Disease, Dementia, Sleep Disorder, Sleep Disturbance
- Trial name
- 40Winks (NCT04533815)
- Testing
- LOCK sleep intervention
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Alabama, Tuscaloosa
Chronic Lymphocytic Leukemia
FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia
The goal of this clinical research study is to learn if using a combination of fludarabine, cyclophosphamide, and rituximab, with sargramostim (GM-CSF) can help to control previously untreated chronic lymphocytic leukemia (CLL).
- Trial name
- NCT00381004
- Testing
- Cyclophosphamide, Fludarabine, Sargramostim
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Lymphocytic Leukemia
Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia
The purpose of this study is to determine the efficacy of bendamustine and rituximab (BR) followed by venetoclax for 12 months. The total time on therapy is 15 months.
- Trial name
- NCT03609593
- Testing
- Bendamustine, Venetoclax, Rituximab
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Nicole Lamanna
Pancreatic Adenocarcinoma
9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma
This trial examines how Pancreatic Adenocarcinoma reacts to the addition of 9-ING-41 and retifanlimab to the standard of care chemotherapy treatment, to see if using this combination will help and is able to effect disease…
- Trial name
- RiLEY (NCT05239182)
- Testing
- 9-ING-41, Retifanlimab, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Anwaar Saeed
High-risk Diffuse Large B-Cell Lymphoma
Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma
A phase 2, multicenter, open-label, single arm clinical trial in adults with newly diagnosed aggressive high-risk DLBCL.
- Trial name
- NCT03023878
- Testing
- Blinatumomab, Investigator's Choice Chemotherapy, Dexamethasone
- Where
- 24 sites in United States, Canada and 4 more
- Volunteers
- 47 people
- Sponsor
- Amgen
Non Small Cell Lung Cancer With Bone Metastatses
BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases
In this study patient's will receive the medicine Xofigo which is a radioactive drug that is FDA approved to treat prostate cancer that has spread to the bones.
- Trial name
- NCT02283749
- Testing
- Xofigo
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Angela Taber MD
Hodgkin Lymphoma
A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
The purpose of this study is to assess the safety profile and antitumor activity of brentuximab vedotin administered in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma (HL)
- Trial name
- NCT02572167
- Testing
- brentuximab vedotin, nivolumab
- Where
- 13 sites in United States
- Volunteers
- 93 people
- Sponsor
- Seagen Inc.
Burnout, Caregiver, Burnout, Professional
Frontline Clinician Psilocybin Study
This study aims to investigate the effects of a single dose of psilocybin, delivered in the contextof pre- and post-dose psychotherapy, on symptoms of depression and burnout suffered by healthcare clinicians as a result of…
- Conditions
- Burnout, Caregiver, Burnout, Professional, COVID-19, Depression
- Trial name
- NCT05163496
- Testing
- Psilocybin (Usona Institute)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Washington
Hodgkin Disease
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
The purpose of this study is to assess the safety, tolerability, and anti-tumor activity, as well as confirm the recommended dose of brentuximab vedotin (ADCETRIS) in combination with a multiagent chemotherapy regimen…
- Trial name
- NCT02979522
- Testing
- Brentuximab vedotin, Doxorubicin, Vinblastine
- Where
- 14 sites in United States, Brazil and 2 more
- Volunteers
- 59 people
- Sponsor
- Takeda
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
This study will utilize Erwinaze via intravenous administration in patients between the ages of 1 and 30 who have experienced an allergy to their frontline therapy.
- Trial name
- NCT01643408
- Testing
- asparaginase Erwinia chrysanthemi
- Where
- 22 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Jazz Pharmaceuticals
COVID-19, COVID-19 Testing
Using MOST to Optimize an Intervention to Increase COVID-19 Testing for Frontline Essential Workers
COVID-19 testing is essential to controlling the COVID-19 pandemic to break transmission chains and reduce community transmission.
- Trial name
- NCAP1 (NCT05139927)
- Testing
- Motivational interviewing (MI) counseling, Text messages (TMs) and quiz questions (QQs), Peer education
- Where
- United States
- Volunteers
- 438 people
- Sponsor
- New York University